Stephen L Chan

Summary

Affiliation: The Chinese University of Hong Kong
Country: China

Publications

  1. doi request reprint Infection and Cancer: The Case of Hepatitis B
    Stephen L Chan
    Stephen L Chan, Vincent W S Wong, and Henry L Y Chan, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People s Republic of China and Shukui Qin, Bayi hospital, Nanjing, People s Republic of China
    J Clin Oncol 34:83-90. 2016
  2. doi request reprint Novel therapeutic targets and predictive markers for hepatocellular carcinoma
    Stephen L Chan
    The Chinese University of Hong Kong, Hong Kong Cancer Institute and Prince of Wales Hospital, State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong, China 852 2632 2118 852 2648 7097
    Expert Opin Ther Targets 19:973-83. 2015
  3. ncbi request reprint Targeting angiogenic genes as a therapeutic approach for hepatocellular carcinoma
    Chi Hang Wong
    Department of Clinical Oncology, The Chinese University of Hong Kong
    Curr Gene Ther 15:97-108. 2015
  4. pmc International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China
    Chin J Cancer 33:481-91. 2014
  5. pmc Systemic treatment for inoperable pancreatic adenocarcinoma: review and update
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology and Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
    Chin J Cancer 33:267-76. 2014
  6. doi request reprint Targeted therapy of hepatocellular carcinoma: present and future
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
    J Gastroenterol Hepatol 27:862-72. 2012
  7. doi request reprint New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy
    Stephen L Chan
    Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
    J Clin Oncol 27:446-52. 2009
  8. doi request reprint A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir Y K Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
    Cancer 118:3984-92. 2012
  9. doi request reprint Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, Hong Kong, China
    J Gastroenterol Hepatol 26:340-7. 2011
  10. doi request reprint Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
    Liver Int 32:271-8. 2012

Collaborators

Detail Information

Publications40

  1. doi request reprint Infection and Cancer: The Case of Hepatitis B
    Stephen L Chan
    Stephen L Chan, Vincent W S Wong, and Henry L Y Chan, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People s Republic of China and Shukui Qin, Bayi hospital, Nanjing, People s Republic of China
    J Clin Oncol 34:83-90. 2016
    ..Finally, the status of the development of targeted drugs specifically for HBV-related HCC is discussed in the section on future development. ..
  2. doi request reprint Novel therapeutic targets and predictive markers for hepatocellular carcinoma
    Stephen L Chan
    The Chinese University of Hong Kong, Hong Kong Cancer Institute and Prince of Wales Hospital, State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong, China 852 2632 2118 852 2648 7097
    Expert Opin Ther Targets 19:973-83. 2015
    ..However, most of the recently published drug trials in HCC failed to produce remarkable results. The researchers are actively pursuing novel therapeutic targets as well as predictive biomarker for treatment of HCC...
  3. ncbi request reprint Targeting angiogenic genes as a therapeutic approach for hepatocellular carcinoma
    Chi Hang Wong
    Department of Clinical Oncology, The Chinese University of Hong Kong
    Curr Gene Ther 15:97-108. 2015
    ..The therapeutic potential of gene therapy for HCC treatment has been demonstrated and further development of anti-angiogenic may result in new treatment option for HCC patients. ..
  4. pmc International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China
    Chin J Cancer 33:481-91. 2014
    ..A more precise staging system for early-stage disease patients is required. ..
  5. pmc Systemic treatment for inoperable pancreatic adenocarcinoma: review and update
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology and Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
    Chin J Cancer 33:267-76. 2014
    ..Here we review the literature on the development of systemic agents for pancreatic cancer, discuss the current choices of treatment, and provide future directions on the development of novel agents. ..
  6. doi request reprint Targeted therapy of hepatocellular carcinoma: present and future
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
    J Gastroenterol Hepatol 27:862-72. 2012
    ..The review also discusses the lessons learned from outcomes of completed clinical trials and provides perspectives on future clinical trials in HCC...
  7. doi request reprint New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy
    Stephen L Chan
    Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
    J Clin Oncol 27:446-52. 2009
    ..The use of serial alpha-fetoprotein (AFP) in monitoring response has not been rigorously evaluated. We aimed to study the clinical value of AFP trend in an attempt to validate AFP as a surrogate serologic end point...
  8. doi request reprint A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir Y K Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
    Cancer 118:3984-92. 2012
    ..The objective of the current study was to evaluate the prognostic significance of serum the IL-10 level in patients with unresectable HCC...
  9. doi request reprint Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, Hong Kong, China
    J Gastroenterol Hepatol 26:340-7. 2011
    ..This study aims to validate CUPI and compare with other published staging systems...
  10. doi request reprint Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
    Liver Int 32:271-8. 2012
    ..In patients who subsequently develop HCC, the impact of antiviral therapy on the outcome of HCC remains unclear...
  11. doi request reprint The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines
    Brigette B Y Ma
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China
    Invest New Drugs 28:107-14. 2010
    ..This study provided the basis for a phase II clinical trial of PXD101 in inoperable hepatitis-B associated HCC...
  12. pmc Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma
    Anthony W H Chan
    Department of Anatomical and Cellular Pathology, State Key Laboratory in Oncology in South China, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
    Dis Markers 2015:564057. 2015
    ..In summary, the AAPR is a novel index readily derived from a simple low-cost routine blood test and is an independent prognostic indicator for patients with HCC regardless of treatment options...
  13. doi request reprint Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
    Herbert H Loong
    Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China
    Radiother Oncol 104:300-4. 2012
    ..This study explored the prognostic significance of the total dose of cisplatin delivered during CRT...
  14. pmc Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients
    Peiyong Jiang
    Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong
    Proc Natl Acad Sci U S A 112:E1317-25. 2015
    ..These results have improved our understanding of the size profile of tumor-derived circulating cell-free DNA and might further enhance our ability to use plasma DNA as a molecular diagnostic tool. ..
  15. doi request reprint Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Cancer Drug Testing Unit, Hong Kong Cancer Institute, Li Ka Shing Institute of Health Sciences and Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong
    Cancer Chemother Pharmacol 71:1417-25. 2013
    ..We aim to study the activity of combined RAD001 and TKI-258 in cell lines and xenograft model of hepatocellular carcinoma (HCC), with reference to the parallel and upstream pathways of Akt-mTOR axis...
  16. doi request reprint Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha
    Brigette B Y Ma
    Department of Clinical Oncology, Sir Y K Pao Centre for Cancer, State Key Laboratory in Oncology in South China, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong SAR, China
    Cancer 119:4145-53. 2013
    ..This study evaluated the activity of 2 schedules of erlotinib in combination with chemotherapy, and the prognostic significance of serum amphiregulin (AREG) and transforming growth factor alpha (TGFa) in metastatic colorectal cancer...
  17. pmc Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Res
    Winnie Yeo
    Department of Clinical Oncology, State Key Lab of Oncology in South China, Prince of Wales Hospital Shatin, Chinese University of Hong Kong, Hong Kong, China
    J Clin Oncol 30:3361-7. 2012
    ..The objectives were to determine dose-limiting toxicity and maximum-tolerated dose (MTD), to assess pharmacokinetics in phase I, and to assess activity of and explore potential biomarkers for response in phase II...
  18. doi request reprint Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection
    Anthony W H Chan
    Department of Anatomical and Cellular Pathology, State Key Laboratory in Oncology in South China, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong
    Ann Surg Oncol 22:4138-48. 2015
    ....
  19. doi request reprint Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
    J Gastroenterol Hepatol 30:1529-35. 2015
    ..We aim to study the applicability of BALAD score and prognostication of the three tumor markers in hepatitis B virus-related HCC...
  20. doi request reprint Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma
    Edwin P Hui
    Partner State Key Laboratory of Oncology in South China, Department of Clinical Oncology, Sir Y K Pao Center for Cancer, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong Special Administrative Region SAR, China
    Cancer 121:2720-9. 2015
    ....
  21. doi request reprint Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome
    Anthony W H Chan
    Departments of Anatomical and Cellular Pathology Clinical Oncology, State Key Laboratory in Oncology in South China, Prince of Wales Hospital Institute of Digestive Disease, Partner State Key Laboratory of Digestive Disease Li Ka Shing Institute of Health Science, Sir Y K Pao Cancer Center Department of Medicine and Therapeutics Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, The Chinese University of Hong Kong, Hong Kong
    Am J Surg Pathol 39:304-12. 2015
    ..In brief, LEL-HCC is a distinct uncommon variant of HCC characterized by dense cytotoxic T-cell infiltration and favorable prognosis. ..
  22. doi request reprint Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response
    Winnie Yeo
    Comprehensive Cancer Trials Unit, Department of Clinical Oncology, State Key Lab in Oncology in South China, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong
    BMC Cancer 15:395. 2015
    ....
  23. doi request reprint Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments
    Kun Sun
    Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China
    Proc Natl Acad Sci U S A 112:E5503-12. 2015
    ..This method may serve as a powerful tool for assessing a wide range of physiological and pathological conditions based on the identification of perturbed proportional contributions of different tissues into plasma. ..
  24. doi request reprint Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?
    Stephen L Chan
    Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China
    Future Oncol 5:889-99. 2009
    ..In this review, the evidence regarding the prognostic value of serum alpha-fetoprotein and the value of serial alpha-fetoprotein in the monitoring of treatment efficacy will be discussed, with emphasis on recent data...
  25. doi request reprint Management of hepatocellular carcinoma: beyond sorafenib
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
    Curr Oncol Rep 14:257-66. 2012
    ..This review aims to summarize the current status of clinical development of treatment in HCC. Perspectives on future direction of research will also be discussed...
  26. pmc Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing
    K C Allen Chan
    Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China
    Proc Natl Acad Sci U S A 110:18761-8. 2013
    ..These developments have thus expanded the applications of plasma DNA analysis for cancer detection and monitoring. ..
  27. pmc Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir Y K Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, Hong Kong, China
    HPB (Oxford) 16:366-72. 2014
    ..This study was conducted to evaluate the performance of AFP in the diagnosis of HCC, and to identify the optimal cut-off value of serum AFP in the diagnosis of HCC in patients with a hepatic mass...
  28. doi request reprint Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma
    Anthony W H Chan
    Department of Anatomical and Cellular Pathology, State Key Laboratory in Oncology in South China, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
    Histopathology 64:935-50. 2014
    ..There are few data on their independent prognostic role in addition to the existing AJCC TNM staging system...
  29. doi request reprint Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin
    Chi Han Li
    School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong
    Gastroenterology 144:1086-1097.e9. 2013
    ..We identified microRNAs (miRs) that are regulated by EZH2 and studied their functions in PDAC cells...
  30. doi request reprint Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients
    Edwin P Hui
    Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Hong Kong Cancer Institute and Li Ka Shing Institute for Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong
    Cancer Res 73:1676-88. 2013
    ..We concluded that MVA-EL is both safe and immunogenic, allowing the highest dose to be forwarded to phase II studies examining clinical benefit...
  31. pmc Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade
    Philip J Johnson
    Philip J Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool Philip J Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service NHS Foundation Trust, Bebington Mabel Teng, Addenbrooke s Hospital, University of Cambridge, Cambridge Helen L Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne James O Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA Winnie Yeo, Frankie Mo, and Stephen L Chan, State Key Laboratory in Oncology in South China, Sir Y K Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong
    J Clin Oncol 33:550-8. 2015
    ....
  32. doi request reprint A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma
    Zhangang Xiao
    School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong
    Cancer Res 74:6236-47. 2014
    ..Taken together, our results offer a preclinical proof of concept for Rubone as a lead candidate for further investigation as a new class of HCC therapeutic based on restoration of miR34a tumor-suppressor function...
  33. ncbi request reprint The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas
    Stephen L Chan
    Cancer Epigenetics Laboratory, State Key Laboratory in Oncology in South China, Department of Clinical Oncology, Sir YK Pao Center for Cancer, Hong Kong
    Lab Invest 87:644-50. 2007
    ..WIF1 methylation could also serve as a specific biomarker for these tumors...
  34. ncbi request reprint Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy
    Winnie Yeo
    Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China
    Hepatology 45:1382-9. 2007
    ..0217; hazard ratio = 1.650; 95% CI 1.076-2.531) affected survival significantly. Exploratory analysis revealed that high levels of pretreatment HBV DNA had a significantly higher incidence of severe hepatitis during chemotherapy...
  35. doi request reprint Novel systemic therapeutic for nasopharyngeal carcinoma
    Stephen L Chan
    The Chinese University of Hong Kong, Hong Kong Cancer Institute and Prince of Wales Hospital, Sir YK Pao Center for Cancer, Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Shatin, Hong Kong
    Expert Opin Ther Targets 16:S63-8. 2012
    ..Therefore, novel therapies based on molecular targets of NPC have become the focus of development...
  36. doi request reprint Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing
    K C Allen Chan
    Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China
    Clin Chem 59:211-24. 2013
    ..Tumor-derived DNA can be found in the plasma of cancer patients. In this study, we explored the use of shotgun massively parallel sequencing (MPS) of plasma DNA from cancer patients to scan a cancer genome noninvasively...
  37. pmc Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma
    Stephen L Chan
    Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, 30 32 Ngan Shing Street, Shatin, Hong Kong SAR, China
    BMC Cancer 6:259. 2006
    ..The mainstay of treatment of metastatic NPC is systemic chemotherapy and resection for solitary metastasis. Despite high response rate to chemotherapy, complete remission is uncommonly seen...
  38. pmc Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights
    Stephen L Chan
    Stephen L Chan, Winnie Yeo, Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
    World J Gastroenterol 20:3135-45. 2014
    ..Future directions for testing innovative systemic agents for HCC will also be discussed...
  39. ncbi request reprint Stereotactic radiotherapy for hepatocellular carcinoma: report of a local single-centre experience
    L C Chan
    Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong
    Hong Kong Med J 17:112-8. 2011
    ..To evaluate the efficacy and toxicities of stereotactic radiotherapy for unresectable hepatocellular carcinoma...
  40. pmc Accomplishments in 2007 in the management of hepatobiliary cancers
    Anthony T C Chan
    The Department of Clinical Oncology at the Sir Y K Pao Centre for Cancer, Hong Kong Cancer Institute and Li Ka Shing Institute for Health Sciences, State Key Laboratory in Oncology in South China, The Chinese University of Hong Kong, Hong Kong, China
    Gastrointest Cancer Res 2:S25-31. 2008
    ....